Millipore Sigma Vibrant Logo

539109 PAR-2 Agonist I - Calbiochem

Descripción

Replacement Information

Tabla espec. clave

Empirical Formula
C₃₁H₅₃N₉O₇

Precios y disponibilidad

Número de referencia DisponiblidadEmbalaje Cant./Env. Precio Cantidad
539109-1MG
Comprobando disponibilidad...
Disponibilidad a confirmar
Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

      Ampolla de plást. 1 mg
      Recuperando precio...
      No pudo obtenerse el precio
      La cantidad mínima tiene que ser múltiplo de
      Maximum Quantity is
      Al finalizar el pedido Más información
      Ahorró ()
       
      Solicitar precio
      539109-5MG
      Comprobando disponibilidad...
      Disponibilidad a confirmar
Disponibilidad a confirmar
      Ingrese cantidad 
      Suspendido
      Cantidades limitadas disponibles
      Debe confirmarse disponibilidad
        El resto: se avisará
          El resto: se avisará
          Se avisará
          Póngase en contacto con el Servicio de Atención al Cliente
          Contact Customer Service

          Ampolla de plást. 5 mg
          Recuperando precio...
          No pudo obtenerse el precio
          La cantidad mínima tiene que ser múltiplo de
          Maximum Quantity is
          Al finalizar el pedido Más información
          Ahorró ()
           
          Solicitar precio
          Description
          OverviewThe native PAR-2-specific agonist, SLIGRL-NH2, is modified with an N-terminal furoyl group to increase its potency and resistance to metabolic degradation. Shown to activate [Ca2+]i mobilization in PAR-2-expressing cells (EC50 = 253 nM using HCT-15 cells) in vitro and induce PAR-2 mediated salivation (ED50 = 30 nmol/kg, i.v.) in vivo, while exhibiting no effect on PAR-2-/- mice. Reactive towards human, rat, and murine PAR-2.
          Catalogue Number539109
          Brand Family Calbiochem®
          SynonymsProteinase Activated Receptor-2 Agonist I, 2f-LIGRL-amide
          References
          ReferencesKawabata, A., et al. 2004. J. Pharmacol. Exp. Ther. 309, 108.
          Kawabata, A., et al. 2004. J. Pharmacol. Exp. Ther. 309, 1098.
          Ferrell, W.R., et al. 2003. J. Clin. Invest. 111, 35.
          Product Information
          ATP CompetitiveN
          FormWhite lyophilized solid
          FormulationSupplied as a trifluoroacetate salt.
          Hill FormulaC₃₁H₅₃N₉O₇
          Chemical formulaC₃₁H₅₃N₉O₇
          Hygroscopic Hygroscopic
          ReversibleN
          Quality LevelMQ100
          Applications
          Biological Information
          Primary TargetPAR-2
          Primary Target IC<sub>50</sub>EC50 = 253 nM as PAR-2-specific agonist using HCT-15 cells
          Purity≥95% by HPLC
          Physicochemical Information
          Cell permeableN
          Peptide Sequence2-Furoyl-Leu-Ile-Gly-Arg-Leu-NH₂
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Hygroscopic Hygroscopic
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications
          Global Trade Item Number
          Número de referencia GTIN
          539109-1MG 04055977195309
          539109-5MG 04055977195316

          Documentation

          PAR-2 Agonist I - Calbiochem Ficha datos de seguridad (MSDS)

          Título

          Ficha técnica de seguridad del material (MSDS) 

          PAR-2 Agonist I - Calbiochem Certificados de análisis

          CargoNúmero de lote
          539109

          Referencias bibliográficas

          Visión general referencias
          Kawabata, A., et al. 2004. J. Pharmacol. Exp. Ther. 309, 108.
          Kawabata, A., et al. 2004. J. Pharmacol. Exp. Ther. 309, 1098.
          Ferrell, W.R., et al. 2003. J. Clin. Invest. 111, 35.
          Ficha técnica

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision02-September-2008 RFH
          SynonymsProteinase Activated Receptor-2 Agonist I, 2f-LIGRL-amide
          DescriptionNative proteinase activated receptor-2- (PAR-2) specific agonist, SLIGRL-NH2, modified with an N-terminal furoyl group to increase its potency and resistance to metabolic degradation. Shown to activate [Ca2+]i mobilization in PAR-2-expressing cells (EC50 = 253 nM in HCT-15 cells) in vitro. Also induces PAR-2-mediated salivation (ED50 = 30 nmol/kg, i.v.) in vivo. Exhibits no effects on PAR-2-/- mice. Reactive towards human, rat, and mouse PAR-2.
          FormWhite lyophilized solid
          FormulationSupplied as a trifluoroacetate salt.
          Intert gas (Yes/No) Packaged under inert gas
          Chemical formulaC₃₁H₅₃N₉O₇
          Peptide Sequence2-Furoyl-Leu-Ile-Gly-Arg-Leu-NH₂
          Purity≥95% by HPLC
          SolubilityDMSO (5 mg/ml)
          Storage +2°C to +8°C
          Hygroscopic
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Standard Handling
          ReferencesKawabata, A., et al. 2004. J. Pharmacol. Exp. Ther. 309, 108.
          Kawabata, A., et al. 2004. J. Pharmacol. Exp. Ther. 309, 1098.
          Ferrell, W.R., et al. 2003. J. Clin. Invest. 111, 35.